乳腺癌内分泌治疗的相关进展

doi:10.6040/j.issn.1671-7554.0.2017.898

摘要/Abstract

摘要： 内分泌治疗是激素受体阳性乳腺癌的主要治疗手段。随着一些重要临床试验证据的出现,内分泌治疗的策略也不断得到更新,包括早期乳腺癌辅助内分泌治疗的延长,卵巢功能抑制的联合应用等,进一步改善了患者的生存。内分泌耐药机制研究的不断深入也为晚期乳腺癌的内分泌治疗提供了新的治疗手段,随着新的药物被开发,包括雌激素受体下调剂、内分泌联合靶向治疗药物的应用,明显改善了患者的预后,显示出良好的临床应用前景。

关键词: 乳腺癌, 激素受体阳性, 内分泌治疗, 靶向治疗, 预后

Abstract: Endocrine therapy is the mainstay treatment for hormone-receptor-positive breast cancer. Based on new evid-ences collected from clinical trials, new strategies have been available and have improved the long-term outcomes of patients, including longer endocrine treatment of early breast cancer, combined use of ovarian suppression, and so on. In parallel with expanding knowledge about the resistance mechanisms to endocrine therapy, new agents for hormone receptor-positive metastatic breast cancer continue to appear. The selective estrogen-receptor degrader, fulvestrant, and new endocrine-target combinations provide significant and clinically meaningful improvements in outcomes. This review will explore the current and investigational approaches to endocrine therapy for hormone-receptor-positive breast cancer.

Key words: Breast cancer, Hormone receptor positive, Endocrine therapy, Target therapy, Prognosis

中图分类号:

R737.9

凌瑞,张聚良. 乳腺癌内分泌治疗的相关进展[J]. 山东大学学报 (医学版), 2018, 56(1): 27-31.

LING Rui, ZHANG Juliang. Advances of endocrine therapy for hormone-receptor-positive breast cancer[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 27-31.

参考文献

[1] Early Breast Cancer Trialists Collaborative Group(EBC-TCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials[J]. Lancet, 2011, 378(9793): 771-784.
[2] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[3] Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol, 2013, 31: 5.
[4] Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2015, 372(5): 436-446.
[5] Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression(TEXT and SOFT): a combined analysis of two phase 3 randomised trials[J]. Lancet Oncol, 2015, 6(7): 848-858.
[6] Regan MM, Francis PA, Pagani O. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials[J]. J Clin Oncol, 2016, 34(19): 2221-2231.
[7] Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219.
[8] Mamounas EP, Lembersky B, Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor(AI)or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer[J]. J Clin Breast Cancer, 2006, 7(5): 416-421.
[9] Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy(DATA): a randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1502-1511.
[10] Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial(BOOG 2006-05)[J]. J Natl Cancer Inst, 2018, 110(1). doi: 10.1093/jnci/djx134.
[11] Nabholtz JM, Buzdar A, Pollak M, et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group[J]. J Clin Oncol, 2000, 18(22): 3758-3767.
[12] Thürlimann B, Hess D, Köberle D, et al. Anastrozole(‘Arimidex’)versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET(Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability)trial[J]. Breast Cancer Res Treat, 2004, 85(3): 247-254.
[13] Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol, 2008, 26: 4883-4890.
[14] Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511.
[15] Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer(FALCON): an international, randomised, double-blind, phase 3 trial[J]. Lancet, 2016, 388(10063): 2997-3005.
[16] Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol, 2012, 30(16): 1919-1925.
[17] Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer[J]. N Engl J Med, 2012, 367(5): 435-444.
[18] Fribbens C, OLeary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2016, 34(25): 2961-2968.
[19] Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
[20] Kornblum NS, Manola J, Klein P, et al. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor(HR)-positive, HER2-negative metastatic breast cancer(MBC)resistant to aromatase inhibitor(AI)therapy[EB/OL].[2016 SABCS S1-02]. https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf
[21] Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer(BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(7): 904-916.
[22] Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18[J]. Breast Cancer Res, 2016, 18(1): 67.
[23] Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936.
[24] Romero D. Breast cancer: MONALEESA-2 and FALCON-PFS advantage[J]. Nat Rev Clin Oncol, 2016, 13(12): 717.
[25] Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients[J]. J Glob Oncol, 2017, 3(4): 289-303.
[26] Rita N, Minetta CL, Douglas Y, et al. Permbrolizumab plus standard neoadjuvant therapy for high risk breast cancer: results from the I-SPY2 trial[EB/OL].[2017-ASCOAbs 506]. https://meetinglibrary.asco.org/record/153653/abstract.

相关文章 15

[1]	林芸,谢燕秋. 乳腺癌患者生育力保护及保存[J]. 山东大学学报 (医学版), 2022, 60(9): 42-46.
[2]	郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.
[3]	王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[4]	高中霞,张铭,樊明德,谭晨阳,王梦迪,王超,樊跃飞,丁守銮,王成伟. 伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素[J]. 山东大学学报 (医学版), 2022, 60(8): 44-49.
[5]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[6]	杨其峰,张宁. 精准医疗时代的乳腺癌前哨淋巴结活检[J]. 山东大学学报 (医学版), 2022, 60(8): 1-5.
[7]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[8]	张玉凤,徐敏,邢秀丽,逄曙光,户克庆. 689例非ST段抬高型心肌梗死患者的临床流行病学特征[J]. 山东大学学报 (医学版), 2022, 60(7): 118-122.
[9]	李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58.
[10]	赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29.
[11]	郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[12]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[13]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[14]	陈立晓,英信江,陈歆维,王菲,孙臻峰,董频. 下咽鳞癌蛋白质谱鉴定及预后靶分子筛选[J]. 山东大学学报 (医学版), 2021, 59(9): 140-147.
[15]	王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed